Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Bypassing conventional trial-and-error methods for solubility challenges and excipient selection can eliminate unnecessary testing, improve the efficacy of your formulation, and increase your overall speed to market.
This study presents how strategic enhancements to the sparge and agitation systems of Thermo Scientific™ HyPerforma™ S.U.B.s have revealed the potential for a three- to four-fold improvement in mixing and mass transfer performance compared to legacy S.U.B. designs.
The aggressive performance demands of industrial microbiology have limited the conversion of traditional fermentation processes into single-use systems. In order to address the unique needs of microbial applications, single-use fermentors have been designed to meet the requirements of microbial fermentation instead of being modified from a cell culture bioreactor.
A collaborative study with a new customer with the objective of taking an existing, smaller preclinical E. coli process previously performed in stainless steel vessels and scaling it up quickly using the Thermo Scientific™ HyPerforma™ 300 L Single-Use Fermentor (S.U.F.)
How far have we come in raw material supply management, and what still needs accomplished to ensure the delivery of safe and effective drugs?
OptiForm® Solution Suite is a comprehensive offering which incorporates everything you need to progress your candidate from late-stage discovery to phase I.
A platform that combines drug development expertise and biomanufacturing and integrated services to offer advantages to ADC developers.
This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.
Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.
The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.
Piramal Pharma Solutions (PPS) is pleased to welcome Ash Stevens LLC as a part of the Piramal Group. Leveraging five decades of Ash Stevens’s operational experience and technical expertise, Piramal’s service offering now includes High Potency API (HPAPI) development and manufacturing capabilities. Located in Riverview, USA, our state-of the-art FDA licensed cGMP facility offers a full range of scale and containment options for high potency API manufacturing.
Leverage an innovative partner with proven expertise in early development to ensure quick problem solving, speed and results.
An integrated solution for Cell Factory systems.
